Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
Mark W Burns, Eric S Kim Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Abstract: Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung can...
Guardado en:
Autores principales: | Burns MW, Kim ES |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/615bc03c1c684229b384790e7c3150d5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise AM, et al.
Publicado: (2014) -
First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015) -
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Marianne Oulhen, et al.
Publicado: (2021) -
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
por: Berghmans T, et al.
Publicado: (2012) -
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi I, et al.
Publicado: (2014)